Hodson, Daniel Z.
Mbarga Etoundi, Yannick
Mbatou Nghokeng, Narcisse
Mohamadou Poulibe, Raïhana
Magne Djoko, Sonia
Goodwin, Justin
Cheteug Nguesta, Glwadys
Nganso, Tatiana
Armstrong, Jillian N.
Andrews, John J.
Zhang, Elizabeth
Wade, Martina
Eboumbou Moukoko, Carole Else
Boum, Yap II
Parikh, Sunil
Funding for this research was provided by:
Wilbur G. Downs International Health Travel Fellowship, Yale School of Public Health
Medical Student Fellowship, Yale School of Medicine
Lowe Endowment Funds, Yale School of Medicine
G.D. Hsiung, PhD Student Research Fellowship, Yale School of Medicine
Benjamin H. Kean Travel Fellowship in Tropical Medicine, American Society of Tropical Medicine & Hygiene
Malaria Research Unit, Pasteur Center of Cameroon
Epicentre
Article History
Received: 10 May 2022
Accepted: 10 October 2022
First Online: 22 October 2022
Declarations
:
: This study was conducted in accordance with ethics directives related to research on humans in Cameroon. The study was approved by the Institutional Committee of Ethics for Research for Human Health of the University of Douala (N° 1617 IEC-UD/ 04/2018/T) and the Yale Human Research Protection Program (HIC #2000023509), and administrative authorization (01800776 14 MAI 2018) was obtained from Douala Military Hospital. All those ≥ 18 years old provided consent, parents/guardians provided consent for minors < 18 years old, and minors aged 8–17 years additionally provided assent. Consent forms were available and approved in both English and French, depending on the preference of the participant and/or guardian. Participants with a positive RDT who did not need to be hospitalized were provided first-line artemisinin-based combination therapy free of charge in accordance with the guidelines from the Cameroon National Malaria Control Programme.
: Not applicable.
: The authors report that they have no competing interests to report relevant to the current study.